Table 1:
Approved and clinical candidate ADC small molecule payloads.
| Name | Brand Name | Payload | Linker | FDA Status |
|---|---|---|---|---|
| Gemtuzumab ozogamicin | Mylotarg | Calicheamicin | Cleavable | Approved |
| Inotuzumab ozogamicin | Besponsa | Calicheamicin | Cleavable | Approved |
| Trastuzumab deruxtecan | Enhertu | Dxd (exatecan derivative) | Cleavable | Approved |
| Datopotamab deruxtecan | Datroway | Dxd (exatecan derivative) | Cleavable | Approved |
| Ado-trastuzumab emtansine | Kadcyla | DM1 (Maytansinoid analog) | Non-Cleavable | Approved |
| Mirvetuximab soravtansine | Elahere | DM4 (Maytansinoid analog) | Cleavable | Approved |
| Brentuximab vedotin | Adcetris | Monomethyl auristatin E (MMAE) | Cleavable | Approved |
| Polatuzumab vedotin | Polivy | Monomethyl auristatin E (MMAE) | Cleavable | Approved |
| Enfortumab vedotin | Padcev | Monomethyl auristatin E (MMAE) | Cleavable | Approved |
| Tisotumab vedotin | Tivdak | Monomethyl auristatin E (MMAE) | Cleavable | Approved |
| Moxetumomab pasudotox | Lumoxiti | Pseudomonas exotoxin (PE38) | Non-Cleavable | Approved |
| Loncastuximab tesirine | Zynlonta | SG3199 (pyrrolobenzodiazepine dimer) | Cleavable | Approved |
| Sacituzumab govitecan | Trodelvy | SN-38 (active metabolite of irinotecan) | Cleavable | Approved |
| Patritumab deruxtecan | N/A | Dxd (exatecan derivative) | Cleavable | In Clinical Trials |
| Telisotuzumab vedotin | Teliso-V | Monomethyl auristatin E (MMAE) | Cleavable | In Clinical Trials |
| Disitamab vedotin | RC48 | Monomethyl auristatin E (MMAE) | Cleavable | In Clinical Trials |
| Depatuxizumab mafodotin | Depatux-M | Monomethyl auristatin F (MMAF) | Non-Cleavable | In Clinical Trials |
| Vadastuximab talirine | N/A | SGD-1882 (pyrrolobenzodiazepine dimer) | Cleavable | In Clinical Trials |
| Camidanlumab tesirine | Cami-T | SG3199 (pyrrolobenzodiazepine dimer) | Cleavable | In Clinical Trials |
| Belantamab mafodotin | Blenrep | Monomethyl auristatin F (MMAF) | Non-Cleavable | Withdrawn |